Dendrimer based nanodevices for therapeutic and imaging purposes
A nanodevice composition including N-acetyl cysteine linked to a dendrimer, such as a PAMAM dendrimer or a multiarm PEG polymer, is provided. Also provided is a nanodevice for targeted delivery of a compound to a location in need of treatment. The nanodevice includes a PAMAM dendrimer or multiarm PEG polymer, linked to the compound via a disulfide bond. There is provided a nanodevice composition for localizing and delivering therapeutically active agents, the nanodevice includes a PAMAM dendrimer or multiarm PEG polymer and at least one therapeutically active agent attached to the PAMAM dendrimer or multiarm PEG polymer. A method of site-specific delivery of a therapeutically active agent, by attaching a therapeutically active agent to a PAMAM dendrimer or multiarm PEG polymer using a disulfide bond, administering the PAMAM dendrimer or multiarm PEG polymer to a patient in need of treatment, localizing the dendrimer or multiarm PEG polymer to a site in need of treatment, and releasing the therapeutically active agent at the site in need of treatment.
1. A method of treating a mother with a first bioactive compound and treating a fetus with a second bioactive compound comprising (i) administering a PAMAM dendrimer linked to the first bioactive compound outside of the placental and amniotic sac barrier to treat the mother with the first bioactive compound and (ii) administering a PAMAM dendrimer linked to the second bioactive compound inside of the placental and amniotic sac barrier to treat the fetus with the second bioactive compound.
2. The method of claim 1 wherein the first bioactive compound treats infection in the mother.
3. The method of claim 2 wherein the infection is or is caused by a disease or agent selected from the group consisting of chorioamnionitis, bacterial vaginosis, ascending genital infection, urinary tract infection, human immunodeficiency virus, Acquired Immunodeficiency Syndronme, herpes virus, Group B streptococcus, and listeriosis.
4. The method of claim 1 wherein the PAMAM dendrimer linked to the second bioactive compound targets a site of neuroinflammation in the fetus.
5. The method of claim 1 wherein the PAMAM dendrimer linked to the second bioactive compound targets activated microglia and astrocytes in the fetus.
6. The method of claim 1 wherein the PAMAM dendrimer linked to the second bioactive compound reduces cerebral palsy in the fetus.
7. The method of claim 1 wherein the second bioactive compound is an anti-inflammatory agent.
8. The method of claim 1 wherein the second bioactive compound is N-acetyl cysteine (NAC).